Insight Molecular Diagnostics (IMDX) Net Cash Flow (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Net Cash Flow data on file, last reported at $16.4 million in Q1 2026.

• Quarterly Net Cash Flow fell 26.62% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 112.8% YoY) and the FY2025 annual result came in at $2.7 million, up 450.13% from the prior year.
• Net Cash Flow rose to $16.4 million in Q1 2026 per IMDX's latest filing, from -$7.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $24.4 million in Q2 2022, with the low at -$15.2 million in Q1 2022.
• Average Net Cash Flow over 5 years is -$458588.2, with a median of -$4.4 million recorded in 2023.
• Year-over-year, Net Cash Flow plunged 304.27% in 2022 and surged 681.53% in 2025.
• Insight Molecular Diagnostics' Net Cash Flow stood at -$10.5 million in 2022, then soared by 58.76% to -$4.4 million in 2023, then soared by 221.26% to $5.3 million in 2024, then sank by 237.91% to -$7.3 million in 2025, then surged by 326.03% to $16.4 million in 2026.
• Business Quant data shows IMDX's Net Cash Flow at $16.4 million in Q1 2026, -$7.3 million in Q4 2025, and -$5.7 million in Q3 2025.